




The relative strengths and weaknesses of Regulus Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Regulus Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 315%, being 61% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	164,951
Cost of Goods Sold	0
Intangible Assets	1,150
Liabilities, Current	35,192
Liabilities, Non-Current	1,022
Other Assets	1,811
Other Compr. Net Income	-181
Other Expenses	40
Other Liabilities	3,252
Other Net Income	-12,118
Other Revenues	8,057
Property and Equipment	3,568
Research and Development	41,046
Selling, General and Administrative Expense	11,533

Output Variable	Value in 1000 USD
Assets	171,480
Liabilities	39,466
Expenses	52,619
Revenues	8,057
Stockholders Equity	132,014
Net Income	-56,680
Comprehensive Net Income	-56,770
BaseVar	141,960
ECR before LimitedLiability	219%
Economic Capital Ratio	315%